Knockdown of m6A methyltransferase METTL3 in gastric cancer cells results in suppression of cell proliferation

Li Jiang, Ting Chen, Xiong Li, Jihao Xu, Ai‐Yu Gong, Bin Dai, Ganlin Wu, Kenny Q. Zhu, Eugene Y. C. Lu, Nicholas W. Mathy, Xian‐Ming ChenOncology 2020 · DOI

Abstract

N6-methyladenosine (m6A) RNA modification regulates multiple biological functions. Methyltransferase like 3 (METTL3), one of the major N6-methyltransferases, is highly expressed in gastric cancer, but its potential role in disease is unclear. The current study knocked out METTL3 (METTL3-KO) in human gastric cancer AGS cells using CRISPR/Cas9. METTL3-KO AGS cells exhibited decreased m6A methylation levels. A significant inhibition of cell proliferation was observed in METTL3-KO AGS cells. Silencing METTL3 in AGS cells altered the expression profile of many effector molecules that were previously demonstrated to serve key roles in AGS cell proliferation, including the suppressor of cytokine signaling (SOCS) family of proteins. The results further demonstrated that SOCS2 upregulation in METTL3-KO AGS cells was associated with a decreased RNA decay rate. Furthermore, SOCS2 KO or SOCS2 overexpression caused a significant increase and decrease in AGS cell proliferation, respectively. The current data suggested that METTL3-KO in gastric cancer cells resulted in the suppression of cell proliferation by inducing SOCS2, suggesting a potential role of elevated METTL3 expression in gastric cancer progression.

TL;DR

METTL3, a key "writer" of m6A RNA methylation, promotes gastric cancer progression by destabilizing the mRNA of the tumor suppressor SOCS2. Knocking out METTL3 stabilizes SOCS2 transcripts, leading to increased protein levels that significantly inhibit cancer cell proliferation.

What Problem Does This Paper Address?

Gastric cancer remains one of the most prevalent and deadly malignancies globally. While previous research indicated that METTL3—an enzyme that adds N6-methyladenosine (m6A) marks to RNA—is overexpressed in gastric cancer tissues, the exact molecular mechanism remained unclear.

The m6A modification is a critical regulator of RNA fate, influencing transcript stability, localization, and translation efficiency. The researchers sought to identify the specific downstream "effector" molecules that METTL3 manipulates to drive the rapid growth of gastric cancer cells.

Methods

The authors employed a suite of molecular biology techniques to dissect the METTL3-SOCS2 axis:

  • CRISPR/Cas9 Gene Editing: Used to create stable METTL3-knockout (KO) clones (C20 and C43) in the AGS human gastric cancer cell line.
  • m6A Quantification: A colorimetric assay confirmed that global m6A levels dropped following METTL3 depletion.
  • RNA Stability Assay: Cells were treated with Actinomycin D to measure the decay rate of existing mRNA transcripts via real-time PCR.
  • Proliferation & Apoptosis Assays: Cell growth was measured using MTS assays and direct cell counting, while Annexin V staining checked for programmed cell death.
  • Rescue Experiments: To confirm the role of SOCS2, the team used both siRNA and plasmid vectors to observe if they could mimic or reverse the effects of METTL3 loss.

Key Insights and Ideas

  • The SOCS2 Connection: While METTL3 knockdown altered the RNA levels of several genes, only SOCS2 showed a significant increase at the protein level. This suggests that in gastric cancer, SOCS2 is the primary functional target of METTL3-mediated regulation.
  • Stability over Transcription: The RNA stability assay revealed that METTL3-mediated m6A marks act as a "destroy" signal for SOCS2 mRNA. Without METTL3, the SOCS2 mRNA is more stable, leading to higher levels of the tumor-suppressing protein.
  • Proliferation, Not Death: The reduction in cell numbers in METTL3-KO cells was due to a slower rate of division (proliferation) rather than an increase in cell death (apoptosis), suggesting METTL3 specifically drives the oncogenic growth cycle.

Key Results

Experimental validation confirmed the successful silencing of the target pathway. As shown in the figure below, knocking out METTL3 resulted in a significant decrease in both METTL3 RNA and protein levels, which directly led to a substantial drop in global m6A methylation levels.

Validation of METTL3 knockout and subsequent reduction in global m6A methylation levels in AGS cells.
  • Global m6A Reduction: Knocking out METTL3 resulted in a ~40-50% drop in global m6A levels in the C43 clone.
  • Growth Inhibition: METTL3-KO cells showed a marked decrease in proliferation compared to wild-type cells over a 96-hour period.
  • SOCS2 Upregulation: Loss of METTL3 led to a significant increase in SOCS2 mRNA stability and a subsequent rise in SOCS2 protein levels.
  • Functional Validation: Overexpressing SOCS2 in wild-type cells inhibited proliferation, while knocking down SOCS2 in METTL3-KO cells partially restored the cancer cells' growth capacity.

Limitations and Future Work

  • In Vivo Validation: The study was conducted entirely in vitro. Animal models (xenografts) are needed to confirm if METTL3 knockdown can shrink tumors in a living system.
  • The "Reader" Protein: While this study identifies the "writer" (METTL3), it doesn't definitively identify the "reader" protein that recognizes the m6A mark on SOCS2 to recruit degradation machinery.
  • Clinical Scope: The study focused on a single cell line (AGS). Testing across a broader range of gastric cancer subtypes would help determine the universality of the METTL3-SOCS2 mechanism.

Summary updated

Abstract

N6-methyladenosine (m6A) RNA modification regulates multiple biological functions. Methyltransferase like 3 (METTL3), one of the major N6-methyltransferases, is highly expressed in gastric cancer, but its potential role in disease is unclear. The current study knocked out METTL3 (METTL3-KO) in human gastric cancer AGS cells using CRISPR/Cas9. METTL3-KO AGS cells exhibited decreased m6A methylation levels. A significant inhibition of cell proliferation was observed in METTL3-KO AGS cells. Silencing METTL3 in AGS cells altered the expression profile of many effector molecules that were previously demonstrated to serve key roles in AGS cell proliferation, including the suppressor of cytokine signaling (SOCS) family of proteins. The results further demonstrated that SOCS2 upregulation in METTL3-KO AGS cells was associated with a decreased RNA decay rate. Furthermore, SOCS2 KO or SOCS2 overexpression caused a significant increase and decrease in AGS cell proliferation, respectively. The current data suggested that METTL3-KO in gastric cancer cells resulted in the suppression of cell proliferation by inducing SOCS2, suggesting a potential role of elevated METTL3 expression in gastric cancer progression.
BibTeX
@inproceedings{jiang2020knockdown,
  author = {Li Jiang and Ting Chen and Xiong Li and Jihao Xu and Ai‐Yu Gong and Bin Dai and Ganlin Wu and Kenny Q. Zhu and Eugene Y. C. Lu and Nicholas W. Mathy and Xian‐Ming Chen},
  title = {{Knockdown of m6A methyltransferase METTL3 in gastric cancer cells results in suppression of cell proliferation}},
  booktitle = {Oncology},
  year = {2020},
  doi = {10.3892/ol.2020.11794},
}
Figure